Biography:
Dr. Brand is a graduate member of the Institute of Biology (GiBiol) and holds a PhD in Molecular Biology from the School of Medicine, University of Manchester, England. He completed his post-doctoral fellowship at Cold Spring Harbor Laboratory, NY. Dr. Brand currently serves as Chief Development Office at Mycovia Pharmaceuticals, providing strategic direction and technical leadership to the clinical development and medical affairs teams. He is responsible for the overall management and performance of the company’s antifungal clinical development programs in women’s health and other areas. Dr. Brand most recently served as Vice President, Clinical Development at Viamet Pharmaceuticals where he led cross-functional project teams, resulting in the successful completion of Phase 2b studies in recurrent vulvovaginal candidiasis and onychomycosis. He previously served as President of Agile Sciences and Director at Argos Therapeutics. Dr. Brand has held senior positions in pharmaceutical development at BioStratum, Inc., and Cato Research Ltd.
Title : A randomized phase 3 clinical study to evaluate the efficacy and safety of SHR8008 (oteseconazole) vs. fluconazole in subjects with vulvovaginal candidiasis (VVC)